noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Peakequity Partners Management Co LLC

PeakEquity Partners Successfully Exits G5
Peakequity Partners Management Co LLC

Thoma Bravo Completes Strategic Investment in PeakEquity Portfolio[...]
Peakequity Partners Management Co LLC

HighLevel Announces Minority Growth Investment from General Atlantic

Healthcare

Pappas Capital LLC

03/04/2024 | Press release | Archived content

Glycomine Announces Encouraging Efficacy Data from Ongoing Phase ...

News | 03. 04. 2024

Glycomine

SAN CARLOS, CA, March 4, 2024 -- Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing Phase 2 clinical study (GLM101-002) in adult patients with PMM2-CDG at the Rare Disease Day 2024 Symposium, CDG Scientific and Family Conference, that took place March 1-3 in San Diego.

Pappas Capital LLC published this content on March 04, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 09:57 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format